Amazon Biotech, Inc. Announces Reverse Split

New York, NY --(MARKET WIRE) - June 4, 2007 -- Amazon Biotech, Inc. (OTC
BB:AMZB.OB - News) (Frankfurt:B2D.F - News) ("Company"), today announced that
the Company has received notice from the National Association of Securities
Dealers, Inc. (the "NASD") that effective at the opening of business on June 6,
2007, the Company has effected a reverse split of its outstanding voting
securities on a basis of one for three.

Dr. Mechael Kanovsky, CEO of Amazon Biotech, explained, "The reverse split is a
very important step to the company's future. Besides the immediate goal of
financing the impending clinical trials, Amazon Biotech is looking for
additional financing for the purpose of restructuring and acquisitions to ensure
that Amazon Biotech will be the leader in whole plant pharmaceuticals."

About Amazon Biotech, Inc.

Amazon Biotech, Inc. is a natural plant pharmaceutical drug company, primarily
developing immunomodulator drugs. AMZ0026 is the Company's first such drug to be
used for the treatment of HIV/AIDS. The Company plans on initiating Phase I/II
clinical studies of AMZ0026 in the near future, with an eventual goal of
partnering with a major pharmaceutical company. Amazon Biotech specializes in
natural whole plant pharmaceutical drugs and is focused on bringing healthier
pharmaceutical drugs to market. Additional information on Amazon Biotech may be
found at:

http://www.amazonbiotech.com/.

Forward-Looking Statements

"Safe-Harbor" Statement Under the Private Securities Litigation Reform Act of
1995: This press release contains forward-looking information within the meaning
of Section 21E of the Securities Exchange Act of 1934, including statements
regarding any potential sales of products as well as statements that include the
words "believes," "expects," "anticipates," or similar expressions. Such
forward-looking statements involve known and unknown risks, uncertainties and
other factors that may cause the actual results, performance or achievements of
Amazon Biotech, to differ materially from those implied or expressed by such
forward-looking statements. Such factors include, among others, the risk factors
included in Amazon Biotech's subsequent reports filed with the Securities and
Exchange Commission under the Exchange Act. This press release speaks as of the
date first set forth above and Amazon Biotech assumes no responsibility to
update the information included herein for events occurring after the date
hereof. Commitment to do a study does not represent that the Company has FDA
approval on the protocol to start the study.


Contact:

      CONTACT:
      LC Group
      Rick Lutz

      (404) 261-1196

lcgroup@mindspring.com